Replimune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. 

CEO
Sushil Patel
CEOSushil Patel
Employees
479
Employees479
Headquarters
Woburn, Massachusetts
HeadquartersWoburn, Massachusetts
Founded
2015
Founded2015
Employees
479
Employees479

REPL Key Statistics

Market cap
796.17M
Market cap796.17M
Price-Earnings ratio
-3.02
Price-Earnings ratio-3.02
Dividend yield
Dividend yield
Average volume
14.66M
Average volume14.66M
High today
$10.61
High today$10.61
Low today
$9.96
Low today$9.96
Open price
$10.36
Open price$10.36
Volume
2.49M
Volume2.49M
52 Week high
$17.00
52 Week high$17.00
52 Week low
$2.68
52 Week low$2.68

REPL News

TipRanks 2d
Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy

Replimune Group ((REPL)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Un...

TipRanks 2d
Replimune’s Innovative Cancer Therapy: A Phase 1 Study Update

Replimune Group ((REPL)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Un...

TipRanks 2d
Bristol-Myers Squibb and Replimune’s Promising Cancer Study: A Potential Game Changer

Bristol-Myers Squibb Company ((BMY)), Replimune Group ((REPL)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take adva...

Analyst ratings

67%

of 9 ratings
Buy
66.7%
Hold
22.2%
Sell
11.1%

More REPL News

TipRanks 3d
Replimune Group’s RP1 Resubmission Boosts Approval Odds and Buy Rating

Replimune Group, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright upgraded the rating on t...

TipRanks 3d
Replimune upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Replimune (REPL) to Buy from Neutral with a $12 price target after the company resubmitted the biologics license application for RP1 pl...

People also own

Based on the portfolios of people who own REPL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.